{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIA+Melanoma", "query": { "condition": "Stage IIA Melanoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IIA+Melanoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T06:46:43.946Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00900302", "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 98, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900302" }, { "nct_id": "NCT02068586", "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Stage I Intraocular Melanoma", "Stage IIA Intraocular Melanoma", "Stage IIB Intraocular Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIC Intraocular Melanoma", "Stage I Uveal Melanoma AJCC V7", "Stage II Uveal Melanoma AJCC V7", "Stage III Uveal Melanoma AJCC V7" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Sunitinib Malate + Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-11-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068586" }, { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT00897442", "title": "Collecting Tumor Samples From Patients With Gynecological Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Borderline Ovarian Clear Cell Tumor", "Borderline Ovarian Serous Tumor", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Small Cell Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Childhood Embryonal Rhabdomyosarcoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Endometrioid Stromal Sarcoma", "Gestational Trophoblastic Tumor", "Malignant Mesothelioma", "Malignant Ovarian Epithelial Tumor", "Melanoma", "Neoplasm of Uncertain Malignant Potential", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Paget Disease of the Vulva", "Recurrent Cervical Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Cervical Cancer", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage III Cervical Cancer", "Stage III Uterine Corpus Cancer", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IV Uterine Corpus Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Uterine Corpus Cancer", "Uterine Corpus Leiomyosarcoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 275, "start_date": "1992-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 187, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897442" }, { "nct_id": "NCT02320305", "title": "MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage IIA Skin Melanoma", "Stage IIB Skin Melanoma", "Stage IIC Skin Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "MART-1 Antigen", "type": "BIOLOGICAL" }, { "name": "TLR4 Agonist GLA-SE", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2015-01-27", "completion_date": "2019-04-11", "has_results": false, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320305" }, { "nct_id": "NCT03028948", "title": "Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage 0 Skin Melanoma", "Stage I Skin Melanoma", "Stage IA Skin Melanoma", "Stage IB Skin Melanoma", "Stage II Skin Melanoma", "Stage IIA Skin Melanoma", "Stage IIB Skin Melanoma", "Stage IIC Skin Melanoma", "Stage III Skin Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 485, "start_date": "2017-01-13", "completion_date": "2020-08-29", "has_results": true, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Charlottesville, Virginia", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03028948" }, { "nct_id": "NCT01826864", "title": "Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB Melanoma", "Stage IIA Melanoma", "Stage IIB Melanoma", "Stage IIC Melanoma" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "sentinel lymph node biopsy", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "hypertonic saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2011-08-05", "completion_date": "2017-08-08", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01826864" }, { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT00735332", "title": "Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "TLN-232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thallion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2008-08", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2010-08-05", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00735332" }, { "nct_id": "NCT03190824", "title": "Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage Iv" ], "interventions": [ { "name": "OBP-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syneos Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-12-22", "completion_date": "2021-10-31", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-05-22T06:46:43.946Z", "location_count": 1, "location_summary": "Morristown, New Jersey", "locations": [ { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190824" } ] }